Idenix, another hepatitis drug developer, was the third-best-performing stock among biotechs in August. Its stock popped after it released abstracts for a medical meeting to be held by the American Association for the Study of Liver Diseases in October, and investors liked what they saw
I suppose this is true, but for something published today, you might think a little qualification would be in order.